首页> 外文期刊>The journal of trauma and acute care surgery >Therapeutic correction of thrombin generation in dilution-induced coagulopathy: Computational analysis based on a data set of healthy subjects
【24h】

Therapeutic correction of thrombin generation in dilution-induced coagulopathy: Computational analysis based on a data set of healthy subjects

机译:稀释性凝血病中凝血酶生成的治疗性校正:基于健康受试者数据集的计算分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Prothrombin complex concentrates (PCCs), which contain different coagulation proteins, are attractive alternatives to the standard methods to treat dilution-induced (and, generally, traumatic) coagulopathy. We investigated the ability of a novel PCC composition to restore normal thrombin generation in diluted blood. The performance of the proposed PCC composition (coagulation factors [F] II, IX, and X and the anticoagulant antithrombin), designated PCC-AT, was compared with that of FVIIa and PCC-FVII, which is the PCC composition containing FII, FVII, FIX, and FX (main components of most PCCs). Methods: We used a thoroughly validated computational model to simulate thrombin generation in normal and diluted blood for 472 healthy subjects in the control group of the Leiden Thrombophilia Study. For every simulated thrombin curve, we calculated and analyzed five standard thrombin generation parameters. Results: The three therapeutic agents (FVIIa, PCC-FVII, and PCC-AT) caused statistically significant changes in each of the five thrombin generation parameters in diluted blood. Factor VIIa tended to primarily impact clotting time, thrombin peak time, and maximum slope of the thrombin curve, whereas in the case of PCC-FVII, thrombin peak height and the area under the thrombin curve were affected particularly strongly. As a result, these two therapeutics tended to push those respective parameters outside their normal ranges. PCC-AT significantly outperformed both FVIIa and PCC-FVII in its ability to normalize individual thrombin generation parameters in diluted blood. Furthermore, PCC-AT could simultaneously restore all five thrombin generation parameters to their normal levels in every subject in the study group. Conclusions: Our computational results suggest that PCC-AT may demonstrate a superior ability to restore normal thrombin generation compared with FVIIa and PCC-FVII.
机译:背景:凝血酶原复合物浓缩物(PCC)包含不同的凝血蛋白,是治疗稀释性(通常是创伤性)凝血病的标准方法的有吸引力的替代方法。我们研究了新型PCC组合物在稀释血液中恢复正常凝血酶生成的能力。将提议的PCC组合物(凝血因子[F] II,IX和X和抗凝血抗凝血酶)的性能(称为PCC-AT)与FVIIa和PCC-FVII(包含FII,FVII的PCC组合物)的性能进行了比较。 ,FIX和FX(大多数PCC的主要组件)。方法:我们使用了经过充分验证的计算模型来模拟莱顿血友病研究对照组的472位健康受试者正常和稀释血液中的凝血酶生成。对于每个模拟的凝血酶曲线,我们计算并分析了五个标准凝血酶生成参数。结果:三种治疗剂(FVIIa,PCC-FVII和PCC-AT)在稀释血液中引起了五个凝血酶生成参数中每一个的统计学显着变化。因子VIIa倾向于主要影响凝血时间,凝血酶峰时间和凝血酶曲线的最大斜率,而在PCC-FVII的情况下,凝血酶峰高和凝血酶曲线下的面积受到特别强烈的影响。结果,这两种疗法倾向于将那些各自的参数推到其正常范围之外。 PCC-AT在稀释血液中的单个凝血酶生成参数正常化的能力方面明显优于FVIIa和PCC-FVII。此外,在研究组的每个受试者中,PCC-AT可以同时将所有五个凝血酶生成参数恢复到正常水平。结论:我们的计算结果表明,与FVIIa和PCC-FVII相比,PCC-AT可能具有更强的恢复正常凝血酶生成的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号